Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock.

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 234 participants.

Also called NCT05817851

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 234 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05817851
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05817851. Randomized; no masking; primary purpose treatment. Start 2023-12-27 (actual); primary completion 2027-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock.
Acronym
VICEPAC
Intervention (Drug)
Vitamin C (Laroscorbine) + Vitamin B1 (Bevitine)
Intervention (Drug)
standard treatment
Lead sponsor
Centre Hospitalier de Bethune (class: research network)
Collaborator
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer (class: other)
Collaborator
University Hospital, Lille (class: other)

Record details

Record id
cardio:ct-nct05817851
Content hash
2a1f0d4cecea4630b5bb49bdfa165f9f2d9c92840040a98f36b61825d05da24b